期刊文献+

人乳头瘤病毒假病毒制备方法的优化 被引量:5

Optimization of Preparation Method for Human Papillomavirus Pseudovirion
下载PDF
导出
摘要 人乳头瘤病毒假病毒可广泛应用于中和抗体鉴定和疫苗免疫性评估等研究.本研究对多质粒共转染293FT细胞生产HPV假病毒的方法进行了深入优化,结果显示不同的HPV结构蛋白表达质粒转染比例对于假病毒生产效率有显著的影响,HPV主要结构蛋白L1的表达水平是影响生产效率的主要因素,L2表达质粒的用量过高或过低均不利于假病毒的生产,而报告质粒的用量对假病毒生产效率的影响相对较小.综合比较显示,在该体系中L1和L2表达质粒和报告质粒以合适比例(如1∶1/10∶1/2)进行共转染可获得更为理想的生产效率.本研究同时也在293FT细胞中对磷酸钙转染方法进行了优化,通过磷酸钙与质粒用量的交叉配比试验获得了较优的转染条件.通过优化,建立了更为高效的HPV假病毒大量制备方法,在HPV16、HPV18、HPV6、HPV11假病毒生产中的应用结果显示较原方法可显著提高生产效率.本研究为HPV假病毒中和实验的规模化应用提供了有利条件. The inability to produce HPV efficiently in animal models or cell culture systems led to the development of alternative approaches for the evaluation of virus-neutralizing antibodies and the study of HPV. In previous research, we have reported that infectious HPV pseudovirion could be economically produced by calcium phosphate eo-transfection of codon optimized HPV16 capsid genes L1 and L2 and reporter plasmid in 293FT cells. Extensive applications of HPV pseudovirion rise the requirement of producing large quantity of pseudovirion. In this report, the pseudovirion producing method was further optimized by testing different quantity ratios of the three plasmids and concentration of DNA in calcium phosphate reagents. Results showed that the producing efficiency of HPV pseudovirion was markedly influenced by different quantity ratios of L1 and L2 expression plasmids,but slightly by different quantity ratio of reporter plasmid. Excessive transfection of either reporter plasmid or L2 expression plasmid led to a decline of L1 expression,along with a lower producing efficiency of pseudovirion, but L2 protein was necessary to generate infectious pseudovirion efficiently. The 1 : 1/10 : 1/2 would be the ideal quantity ratio of L1 and L2 expression plasmids and reporter plasmid in the producing system. The producing efficiency of HPV pseudovirion could be further improved by optimizing the volume of calcium phosphate reagents and the concentration of total plasmids. Results of the cross experiment showed that 37.5 μg/mL and 800 μL would be the ideal concentration of total plasmids and volume of calcium phosphate reagents for 9. 0 × 10^5 293FT cells cultured in 6-well plate. Compared with previous method, the optimized method could achieve higher producing efficiency of HPV pseudovirion, including HPV16, HPV18, HPV11, HPV6 pseudovirion. The optimized method developed in this study facilitate the application of pseudovirion-based human papillomavirus neutralization assay in large scale.
出处 《厦门大学学报(自然科学版)》 CAS CSCD 北大核心 2009年第2期269-273,共5页 Journal of Xiamen University:Natural Science
基金 福建省科技重大专项(2004YZ01) 福建省自然科学基金(C0710041) 厦门市病毒性疾病新药研发平台建设项目(3502Z20041008)资助
关键词 人乳头瘤病毒 假病毒制备 表达质粒 Human papillomavirus pseudovirion preparation experssion plasmids
  • 相关文献

参考文献14

  • 1Finnen R L, Erickson K D, Chen X S, et al. Interactions between papillomavirus L1 and L2 capsid proteins[J]. J Virol, 2003,77(8) :4818-4826.
  • 2Schiller J T, Davies P. Delivering on the promise: HPV vaccines and cervical cancer[J]. Nat Rev Microbiol,2004, 2(4):343--347.
  • 3Koutsky L A,Galloway D A, Holmes K K. Epidemiology of genital human papillomavirus infection[J]. Epidemiol Rev, 1988,10 : 122-- 163.
  • 4Bedell M A,Hudson J B,Golub T R,et al. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation[J]. J Virol, 1991,65 (5) : 2254 -- 2260.
  • 5Pastrana D V, Buck C B, Pang Y Y, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus- based papillomavirus neutralization assay for HPV16 and HPV18[J]. Virol,2004,321 (2):205--216.
  • 6Pyeon D, Lambert P F, Ahlquist P. Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation[J]. Proc Natl Acad Sci USA,2005,102(26) :9311--9316.
  • 7Buck C B, Thompson C D, Pang Y Y, et al. Maturation of papillomavirus eapsids [J ]. J Virol, 2005,79 (5) : 2839 - 2846.
  • 8卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 9Buck C B,Pastrana D V, Lowy D R,et al. Efficient intracellular assembly of papillomaviral vectors[J]. J Virol,2004,78(2):751--757.
  • 10程通,许辰煜,王颖彬,陈敏,吴婷,谢小燕,张军,夏宁邵.杆状病毒用于哺乳动物细胞快速高效表达外源基因的研究[J].生物工程学报,2003,19(5):581-586. 被引量:5

二级参考文献28

  • 1Carbonell L F, Miller L K. Baculovims interaction with nontarset organisms:a vs-borne reposter gene is not expressed in two mammalian cell lines. Appl Environ Micro Biol, 1987,53:1412- 1417.
  • 2Hofmann C, Sandig V, Strauss M et al. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA,1995,92:10099 - 10103.
  • 3Boyce F M, Bucher N L R. Baculovirus mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA, 1996 , 93 : 2348 - 2352.
  • 4Condreay J P, Witherspoon S M, Clay W C et al. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector, Proc Natl Acad Sci USA, 1999,96( 1 ) : 127 - 132.
  • 5Duisit G, Saleun S, Douthe S et al. Baculovirus vector require selectrostatic interactions including heparan sulfate for efficient gene transfer in mammalian cells. J Gene Med, 1999,1(2):93 - 102.
  • 6Delaney W E, lsom H C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus.Hepatology, 1998,28 : 1134 - 1146.
  • 7Bae-to-Bae baculovirus expression systems instruction manual. Invitrogen life technologies,2002.
  • 8Shoji I, Aizaki H, Tani H et al. Efficient gene transfer into various mammalian cells, including non-hepatic cells, by baculovirus vectors.J Gen Virol, 1997,78:2657 - 2664.
  • 9Kost T A, Condreay J P. Recombinant baculoviruses as mammalian cell gene-delivery vectors.Trends biotechnol,2002,20(4):173-180
  • 10Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective, lnt J Cancer, 2004, 111(2):278 - 285

共引文献16

同被引文献32

  • 1卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 2Zhou J,Sun XY,Stenzel DJ. Expression of vaccinia recombinant HPV 16 L1 and L20RF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles[J].Virology,1991,(01):251-257.
  • 3Schiller JT,Castellsague X,Villa LL. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results[J].Vaccine,2008,(10):53-61.
  • 4Descamps D,Hardt K,Spiessens B. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention:a pooled analysis of 11 clinical trials[J].Hum Vaccin,2009,(05):332-340.
  • 5Paavonen J,Naud P,Salmeron J. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRI-CIA):final analysis of a double-blind,randomised study in young women[J].The Lancet,2009,(9686):301-314.doi:10.1016/S0140-6736(09)61248-4.
  • 6World Health Organization Expert Committee on Biological Standardization. Guidelines to assure the quality,safety and efficacy of recombinant human papillomavirus virus-like particlevaccines.Geneva[OL].http://www.who.int./ biologicals/publications/trs/areas/vaccines/humanpapillomavirus/HPV g% 20Final%20BS% 202050%20.pdf,.
  • 7Yeager MD,Aste-Amezaga M,Brown DR. Neutralization of human papillomavirus (HPV) pseudovirions:a novel and efficient approach to detect and characterize HPV neutralizing antibodies[J].Virology,2000,(02):570-577.doi:10.1006/viro.2000.0674.
  • 8Pastrana DV,Buck CB,Pang YY. Reactivity of human sera in a sensitive,high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18[J].Virology,2004,(02):205-216.doi:10.1016/j.virol.2003.12.027.
  • 9Dessy FJ,Giannini SL,Bougelet CA. Correlation between direct ELISA,single epitope-based inhibition ELISA and pseudovifion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine[J].Hum Vaccin,2008,(06):425-434.
  • 10Harper DM,Franco EL,Wheeler C. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women:a randomised controlled trial[J].The Lancet,2004,(9447):1757-1765.

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部